Connect with us

Cannabis News

Tilray advances UK healthcare platform while prepares for U.S. rescheduling

Published

on

Tilray has announced a number of strategic initiatives to mark the next phase of its global growth, expanding across healthcare, cannabis and beverages, strengthening its ability to expand internationally and capture emerging market opportunities.

Irwin D. Simon, President and CEO of Tilray Brands, stated: “Tilray Brands is setting the pace for global innovation in healthcare, cannabis and craft beverages – each a distinct growth engine on our platform. This is a crucial time as we enter the next phase of global growth. We are executing carefully against our strategic plan by expanding our international brand growth icon position and Brewver’s international medical icon position. At the same time, our brands, We maintain the financial flexibility to invest behind infrastructure and capabilities.Together, these actions position Tilray as a broad and diversified global platform with multiple near- and long-term growth drivers, and one of the most dynamic and exciting consumer companies today.

© Tilray Marks

Tilray expands UK Medical Platform with acquisition of Lyphe
Tilray acquired Lyphe Group, a leading UK-based medical cannabis clinic and digital pharmacy platform, with Lyphe Dispensary dispensing around 150,000 units and Lyphe Clinic treating over 16,000 patients to date, anchoring and expanding Tilray Medical’s footprint in one of Europe’s largest and most dynamic healthcare markets. The addition of Lyphe strengthens Tilray’s vertically integrated medical ecosystem, combining clinical services, patient access and pharmaceutical distribution. Through Lyphe’s online clinic and pharmacy platform, Tilray will improve access to medical cannabis while accelerating its traditional prescription drug delivery capabilities, creating a seamless digital patient experience.

Most importantly, with the addition of the Lyphe Group, Tilray Medical is establishing its first fully vertically integrated medical platform, which combines the cultivation and production of pharmaceutical-grade medical cannabis with clinical care, distribution services and pharmaceutical distribution. The integration of Lyphe’s highly skilled patient care team further differentiates this model, enabling a more personalized, unified and comprehensive approach to patient care and outcomes. Tilray will also leverage CC Pharma’s established scale, supply capabilities and purchasing power to supply medicines more efficiently through the Lyphe platform, supporting the wider needs of UK patients and further strengthening Tilray’s European pharmaceutical distribution network.

Rajnish Ohri, International President, Tilray Brands, said: “I am proud to welcome the Lyphe team to Tilray, bringing deep clinical experience and a strong patient-first approach, which immediately strengthens our capabilities. This acquisition marks an important step in Tilray Medical’s continued expansion as a global healthcare platform. We look forward to enhancing our capabilities, our ability to serve UK patients, and the international medical ecosystem in 2027. to build a fully connected, consistent, high-quality care while expanding access to cannabis and traditional therapies.

BrewDog and the beverage platform: Accelerate growth, scale globally and invest in expansion
Six weeks after Tilray acquired BrewDog, the company has moved with speed and discipline to stabilize and strengthen the platform, positioning the brand for its next phase of growth. Tilray has stabilized beer volumes, maintained service levels across channels to ensure consistent stock availability and has begun onboarding new distribution and strategic partners to support expansion.

Mr Simon added: “Our priorities are clear: to strengthen BrewDog, accelerate innovation and scale our global beverage platform. We are already taking decisive steps to reinvest in the BrewDog brand, the innovation pipeline and the brewpub experience, and we see a clear path to rebuilding BrewDog. In the US, we are leveraging our infrastructure and distribution network for our broader beverage portfolio in key growth markets, including the Middle East and India. to scale and support the growth of our American craft brands and global partners like Carlsberg across the US.

Tilray expects the BrewDog business to be cash flow positive by 2027 and is investing in the brand and to revitalize and modernize the existing brewpub estate – areas that have seen limited investment in recent years. This provides a strong foundation for improving performance through targeted operational improvements and focused brand building. These efforts are focused on reimagining the brewpub experience to better connect with today’s consumers to ensure long-term brand relevance. As part of enhancing the venue experience with modern activations, strengthening brand engagement and aligning with evolving consumer preferences, Tilray will invest in a “brewpub of the future” at one of its existing locations, allowing it to analyze, evaluate and recommend future changes to its brewpub network. Tilray BrewDog is building a more compelling platform for the future.

Tilray is seeing strong and growing demand for its American craft portfolio in the UK, creating near-term opportunities to expand distribution and build brand presence in the market. Building on this momentum, the Company plans to launch Hi*Ball Energy in the UK in May, further expanding the beverage offering and increasing consumer demand in the growing functional drink category.

Positioned for US reprogramming and medical cannabis options
In the United States, we are closely following medical cannabis rescheduling and actively engaging with legislators and regulators as they evaluate and work on this important drug policy development. We are also evaluating our participation in the Center for Medicare and Medicaid Innovation pilot program, an opportunity to partner with Healthcare Organizations and oncology practices to provide hemp-derived medical cannabis to underserved and vulnerable patients, provide safe and therapeutic access to medical cannabinoids, and collect data on patient outcomes.

Denise Faltisch, Director of Strategy and Head of M&A, Tilray Brands, stated: “In retrospect, Tilray Medical is strategically positioned to participate in the US medical cannabis market, given our proven track record of operating at scale in highly regulated medical cannabis markets globally, our pharmaceutical quality systems and scientific research, backed by scientific education and scientific research. It will happen in the near term and when it does, we are well positioned to seize the opportunity.”

Through our global Tilray Medical platform, Tilray Medical offers extensive experience in pharmaceutical-grade cultivation, manufacturing and distribution, clinical research and regulatory expertise based in more than 20 markets worldwide. Tilray Medical has helped hundreds of thousands of patients worldwide and offers an extensive portfolio of medical cannabis products, including CBD and THC: beverages, edibles and topicals.

Tilray Introduces ATM Program to Accelerate Global Beverage Expansion
To support this next phase of growth, Tilray has also announced that it will introduce a market equity program (the “ATM program”) of up to $180 million to improve financial flexibility and invest behind its global beverage platform. The ATM program will be managed by Jefferies LLC, TD Securities (USA) LLC and Roth Capital Partners LLC.

For more information:
Tilray
www.tilray.com

Cannabis News

Health Canada opens consultations to deregulate hemp

Published

on

By

Health Canada has published a Notice of Intent to “simplify” the Industrial Hemp Regulation to “eliminate or reduce regulatory burden,” which could include removing the licensing requirement for certain industrial hemp activities, and is asking the industry what changes it wants to see before June 30, 2026.

The announcement acknowledges that “industry stakeholders have advocated for a new approach to regulating industrial hemp that treats it as an agricultural product” and that although industrial hemp and cannabis belong to the same plant family, “the productions and products resulting from the cultivation and processing of industrial hemp are completely different and pose very different risks.” CBD is “non-intoxicating,” the release states, and hemp “has less potential for public health harm and misuse and less public safety concerns compared to cannabis due to its extremely low THC levels.”

© Colin Temple | Dreamstime

Under the current framework, industrial hemp is listed in Schedule 1 of the Cannabis Act along with high-THC cannabis, even if it contains 0.3% THC or less by weight in the flower heads and leaves. To cultivate, sell, import or export seeds or grains, clean seeds, process grains or grow hemp, operators need a separate license for each activity, plus a separate permit for each import or export shipment. Anyone licensed to cultivate the seeds must test the flower heads and leaves for THC concentration, and all cultivated varieties must appear on Health Canada’s List of Approved Crops. Imported seeds also require phytosanitary certification according to CFIA frameworks. Mature stems, non-viable seeds and their derivatives are already out of the field, sitting on tab 2.

The review calls for eliminating or reducing licensing requirements, removing the separate layer of import/export permits, cutting reporting obligations, revamping the List of Approved Crops, reducing or eliminating THC testing requirements and potentially changing the 0.3% THC definition itself. That said, Health Canada is clear that some controls are being left out, specifically to “prevent the illegal cultivation and diversion of cannabis disguised as industrial hemp into an illegal market,” and that international reporting obligations remain an “important consideration.” Extracting CBD from flower heads is also out of scope, as this requires a cannabis processing license under the Cannabis Regulations.

A separate cost-benefit questionnaire goes directly to current IHR licensees, and the responses feed into the regulatory Impact Analysis Statement required by Health Canada before any proposed amendment reaches the Canada Gazette.

Source: magazine.gc.ca

Continue Reading

Cannabis News

Cannabis Advocacy Groups Push Congress For Legalization And Other Reforms Following Trump’s Rescheduling Move

Published

on

By

“Cannabis reform is the hottest topic in American politics, and … Congress is on course to pass a comprehensive legalization bill that targets the release of cannabis prisoners.”

Author: Jack Gorsline, Filter

A national coalition 41 advocacy groups gathered on Capitol Hill for Cannabis Unity WeekA coordinated lobbying blitz pressed a deadlocked Congress to act on federal marijuana deprogramming, criminal law reform, and fair access.

The May 12-14 mobilization brought together unions, veterans, civil liberties advocates, legal experts, industry executives and individuals directly affected by three main demands: federal cannabis legalization, the release of federal cannabis prisoners, and the expungement of civil rights restoration records. The coalition spent three days navigating the halls of both houses of Congress to introduce a comprehensive package of 13 hemp and cannabis reform bills.

The legislative push comes at a critical time. The vast majority of states have legalized medical or adult use of cannabis in some form, and although the Trump administration rescheduled state legal medical marijuana last month, federal law otherwise continues to classify the plant as a Schedule I controlled substance, creating a legal and economic paradox that advocates say can no longer be ignored.

The coalition’s main thrust is the Marijuana Opportunity Reinvestment and Elimination (MORE) Act, introduced as HR 5068. If passed, the MORE Act would completely remove cannabis from the Controlled Substances Act, ending nearly a century of federal prohibition.

The bill’s provisions go beyond simple deprogramming. It aims to eliminate all federal penalties for marijuana activity, establish clear pathways to expungement and reentry, and create community reinvestment with federal cannabis tax revenue. The bill also includes equity measures designed to lower barriers to entry for small and independent businesses trying to navigate the highly capitalized legal market.

“Cannabis reform is a hot topic in American politics, and now that the president has indicated he’s open to reform, it’s up to Congress to pass a comprehensive legislative bill that targets the release of cannabis prisoners who no longer need to be incarcerated,” Jason Ortiz, director of strategic initiatives at the Last Prisoner Project and Co-founder of the Latino Cannabis Alliancehe said The filter.

Ortiz emphasized that the administrative gesture must be supported by specific legislative moves. “The LPP is ready to work with the co-chairs of the Cannabis Caucus and the Cannabis Unity Coalition to pass a comprehensive deprogramming bill like the MORE Act,” he continued, “to finally end the nightmare that has been cannabis prohibition, and create a pathway for all those incarcerated for cannabis offenses to reunify their families and become full members of society.”

A central theme of Unity Week was the disproportionate impact of federal prohibition on minority communities, particularly Latinos. At a May 13 news conference outside the Senate wing of the Capitol, advocates drew a direct line from the anti-immigrant rhetoric of the early 20th century to today’s deportation statistics.

“Buenos dias. My name is Jessica Gonzalez. I’m an Ecuadorian immigrant, attorney, and president of the Latino Cannabis Alliance, a national coalition of Latino advocates, lawyers, organizers, researchers, and storytellers fighting to move our communities from the margins of cannabis politics to the center,” Gonzalez told reporters and lawmakers. “We’re Harry Anslinger’s worst nightmare.”

Anslinger, the first commissioner of the Federal Bureau of Narcotics, weaponized prejudice against Latinos and blacks in the 1930s to secure the initial federal crackdown on cannabis. Gonzalez noted that the structural machinery built at that time continues to operate with remarkable efficiency.

“We’re here because Latinos are the largest immigrant group in the country, and the cannabis industry benefits enormously from Latino consumers and workers because they remain silent on the same policies that make participation by non-citizen Latinos dangerous,” Gonzalez said. “That’s a contradiction we’re here to say out loud. And here’s a number we don’t hear often enough: 70 percent. More than 70 percent of people convicted federally of cannabis possession are classified as Hispanic. That’s not a coincidence, it’s the result of a system that has merged cannabis prohibition and immigration enforcement into a deportation pathway and targeted our families.”

For noncitizens, as well as legal residents, federal convictions or possession of cannabis can result in mandatory deportation without judicial discretion. Gonzalez noted that the Latino Cannabis Alliance refuses to let the economic boom of state-sanctioned cannabis eclipse the human cost of federal action.

“But we have never been a town that accepts the conditions given to us,” said Gonzalez. “My family refused when they left everything they knew and built a life in a foreign country. Our communities refused when prohibition tried to turn our families into criminals and our neighborhoods into evidence. And today, the Latino Cannabis Alliance refuses to deport one more family, silence one more worker, or erase one more community from a movement we’ve always been.”

He continued, “decriminalization is the floor, not the ceiling. We will not forget the deportees. We will not forget the detainees. Our work takes borders, but it begins where this system was built. The ban began with a lie about our people. It will end with the truth we made.”

Business leaders also described the injustice and inequality of the current landscape.

“Cannabis Unity Week is not a celebration of victory, it’s a call to action,” said Susie Plascencia, founder of Latinas in Cannabis and representative of the National Hispanic Cannabis Council. “Thousands of people are still incarcerated for cannabis crimes, families are still living with the consequences of prohibition, and Latino communities remain disproportionately harmed and underrepresented in this industry.”

Today, Plascencia noted, multi-state marijuana operators generate billions of dollars in public markets, but minority-owned independent startups face severe capital constraints due to federal bank restrictions.

“Latino entrepreneurs are among the fastest growing in the country, building businesses despite systemic barriers,” he said., “But in cannabis, many still face limited access to capital, restrictive policies and exclusion from ownership. We’re building it anyway, but we don’t have to build it alone. We’re here to demand federal action… Because equity isn’t just about repairing damage, it’s about investing in the future.”

The broader drug policy reform movement also gave the coalition its institutional weight.

“As MAPS celebrates its 40th anniversary, we are proud to join the Cannabis Unity Coalition to advance the movement for compassionate, evidence-based drug policy,” said Gina Vensel, Community Partnerships Manager for the Multidisciplinary Association for Psychedelic Studies (MAPS).

“This milestone is an opportunity to reflect on the progress made in the War on Drugs case while recognizing the crucial work that still lies ahead, especially around restorative justice,” Vensel said. The filter. “Together, we strive to dismantle stigma, educate our communities, and advocate for meaningful reform. The Cannabis Unity Coalition represents the power of collective action to drive lasting, positive change.”

Beyond the comprehensive scope of the MORE Act, advocates spent time on the Hill educating lawmakers on narrower measures designed to solve immediate practical problems.

Among them is the STATES 2.0 Act (HR 2934), a bipartisan bill that would amend federal law to respect state legal cannabis programs while protecting state-regulated businesses from federal interference and asset forfeiture. Advocates also pushed for the PREPARE Act (HR 2935 / S 3576), which would have created a federal commission charged with designing a comprehensive regulatory framework for the post-prohibition transition.

To address the decades-long decline in political motivation for scientific research, the coalition also sponsored the Evidence-Based Drug Policy Act (HR 3082) to remove barriers that prevent the Office of National Drug Control Policy from conducting objective research on the social impacts of cannabis legalization.

The coalition also focused heavily on “clean slate” initiatives, housing stability and agricultural guidelines. Key legislation in this area includes the Clean Slate Act, a bipartisan measure that mandates the unsealing of certain federal records for nonviolent cannabis convictions to help affected individuals access employment and educational opportunities. Advocates are also championing the Veterans Safe Use of Cannabis for Healing Act and the Veterans Equal Access Act — additional bills to prevent Veterans Affairs benefits from being stripped away if veterans participate in illegal cannabis programs, and to allow VA doctors to prescribe medicinal cannabis in states where it is legal.

Another item on the coalition’s agenda is the Marihuana Federally Assisted Housing Parity Act, a state-enforced measure to protect people in federally assisted housing from eviction or denial of residency based solely on cannabis use. Finally, organizers are seeking clarification on hemp regulations through a series of farm bills.

As the coalition faced a fight against the entrenched Congress leadership, several lawmakers came out of their offices to show solidarity. After the press conference, Representative Ilhan Omar (D-MN) spoke plainly TMZ About changing currents inside the Capitol.

Omar noted that the enormous financial fallout of maintaining prohibition has fundamentally changed the conversation, making fiscal conservatives increasingly open to reform.

“I will say, legalization advocacy doesn’t necessarily mean you’re a user, so everybody can be an advocate … because we understand that it’s not good for us to spend the billions of dollars that we make now incarcerating people for smoking a port,” Omar said.

Omar also suggested that the Hill’s policy positions lag behind private reality. “I think so There are a lot of people in Congress who smoke cannabis“, he said.

As the three-day rally ended, organizers were optimistic, saying the breadth of the 41-group alliance is forcing lawmakers to view cannabis not as a boutique policy issue, but as a critical intersection of labor rights, immigration justice, veterans’ health care and economic equity, among others.

Whether their unity can propel legislative movement in a deeply polarized Congress remains to be seen, but advocates left Washington with a clear message: the floor for decriminalization has been set; the battle for the ceiling of total justice is underway.

This the article Originally published by the author The filteran online magazine that deals with drug use, drug policy and human rights from a harm reduction perspective. Keep the filter on Bluesky, X or Facebookand sign up for their newsletter.

Marijuana Moment is made possible with the help of readers. If you rely on our pro-cannabis journalism to stay informed, consider a monthly Patreon pledge.

Continue Reading

Cannabis News

More cannabis companies join Texas medical marijuana program as list of potentials hits 15

Published

on

By











Texas public safety officials have tentatively approved a dozen cannabis providers to join the state’s medical marijuana program. It’s an important step in expanding access to medical cannabis, after lawmakers voted last year to grow the system from three licensed operators to 15, state officials said.

The companies selected cover nearly every corner of Texas, from the Dallas area and the Panhandle to the Rio Grande Valley and West Texas, reflecting what supporters hope will become a statewide network. Among the 12 suppliers selected to move forward in the final approval process are four companies added since December. Then the Texas Department of Public Safety, which oversees the “Compassionate Use Program,” released an initial list of nine conditionally accepted applicants.

When completed, the licenses will allow the companies, many of them based in Texas, to grow, manufacture, store and sell throughout the state.

“DPS will request additional information from these businesses and will not bill the distributor organization licensing fees until additional due diligence evaluations are completed and passed,” DPS officials said in a statement.

Read more at Dallas Morning News










Continue Reading
Advertisement

Trending

Copyright © 2021 The Art of MaryJane Media